MX2022013753A - Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. - Google Patents
Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.Info
- Publication number
- MX2022013753A MX2022013753A MX2022013753A MX2022013753A MX2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- treatment
- amino acid
- acid compounds
- respiratory diseases
- Prior art date
Links
- -1 amino acid compounds Chemical class 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021674P | 2020-05-07 | 2020-05-07 | |
| PCT/US2021/030363 WO2021225912A1 (en) | 2020-05-07 | 2021-04-30 | Treatment of respiratory diseases with amino acid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013753A true MX2022013753A (es) | 2023-01-30 |
Family
ID=78468277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013753A MX2022013753A (es) | 2020-05-07 | 2021-04-30 | Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181546A1 (enExample) |
| EP (2) | EP4520329A3 (enExample) |
| JP (1) | JP2023524970A (enExample) |
| KR (1) | KR20230049584A (enExample) |
| CN (1) | CN115989235A (enExample) |
| AU (1) | AU2021268889A1 (enExample) |
| CA (1) | CA3173761A1 (enExample) |
| IL (1) | IL297969A (enExample) |
| MX (1) | MX2022013753A (enExample) |
| WO (1) | WO2021225912A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| TW202235417A (zh) * | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| US20230028658A1 (en) * | 2021-04-30 | 2023-01-26 | Pliant Therapeutics, Inc. | Expanded dosage regimens for integrin inhibitors |
| US20240122930A1 (en) * | 2022-07-09 | 2024-04-18 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| EP4626878A1 (en) | 2022-12-02 | 2025-10-08 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| WO2024125634A1 (zh) * | 2022-12-16 | 2024-06-20 | 西藏海思科制药有限公司 | 一种四氢萘啶类化合物及其在医药上的应用 |
| WO2024235299A1 (zh) * | 2023-05-17 | 2024-11-21 | 西藏海思科制药有限公司 | 一种羧基衍生物及其在医药上的应用 |
| WO2025067384A1 (zh) * | 2023-09-28 | 2025-04-03 | 成都微芯药业有限公司 | 一类氨基酸整联蛋白抑制剂、其制备方法及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ502546A (en) * | 1997-08-08 | 2002-02-01 | Univ California | Treatment of acute lung injury and fibrosis with antibodies to alpha-v-beta-6 |
| DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
| EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| JP2018514568A (ja) * | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
| US10118929B2 (en) * | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| WO2018183795A1 (en) * | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
| CU24684B1 (es) * | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| MX2021004173A (es) * | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
-
2021
- 2021-04-30 KR KR1020227042773A patent/KR20230049584A/ko active Pending
- 2021-04-30 MX MX2022013753A patent/MX2022013753A/es unknown
- 2021-04-30 WO PCT/US2021/030363 patent/WO2021225912A1/en not_active Ceased
- 2021-04-30 CN CN202180048580.XA patent/CN115989235A/zh not_active Withdrawn
- 2021-04-30 EP EP25152378.3A patent/EP4520329A3/en not_active Ceased
- 2021-04-30 JP JP2022567249A patent/JP2023524970A/ja not_active Withdrawn
- 2021-04-30 CA CA3173761A patent/CA3173761A1/en active Pending
- 2021-04-30 AU AU2021268889A patent/AU2021268889A1/en not_active Abandoned
- 2021-04-30 EP EP21799675.0A patent/EP4146264A4/en not_active Withdrawn
- 2021-04-30 US US17/923,899 patent/US20230181546A1/en not_active Abandoned
- 2021-04-30 IL IL297969A patent/IL297969A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021268889A1 (en) | 2022-12-15 |
| JP2023524970A (ja) | 2023-06-14 |
| CN115989235A (zh) | 2023-04-18 |
| CA3173761A1 (en) | 2021-11-11 |
| EP4520329A2 (en) | 2025-03-12 |
| EP4146264A4 (en) | 2024-07-24 |
| EP4146264A1 (en) | 2023-03-15 |
| IL297969A (en) | 2023-01-01 |
| KR20230049584A (ko) | 2023-04-13 |
| US20230181546A1 (en) | 2023-06-15 |
| EP4520329A3 (en) | 2025-05-14 |
| WO2021225912A1 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4520329A3 (en) | Treatment of respiratory diseases with amino acid compounds | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| CR20210224A (es) | Compuestos de amoniácidos y métodos de uso | |
| MX2022005232A (es) | Degradadores de moleculas peque?as de helios y procedimientos de uso. | |
| JOP20200212A1 (ar) | مركبات حمض أميني وطرق استخدامها | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| PH12021552881A1 (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| CR20210041A (es) | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso | |
| PH12021552930A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| EA201700077A1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| EA201991615A1 (ru) | Композиция маннуроновой дикислоты | |
| WO2010088000A3 (en) | Antifibrotic compounds and uses thereof | |
| DOP2003000678A (es) | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| PH12021550767A1 (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| MX2021009659A (es) | Hidroxipiridoxazepinas como activadores de nrf2. | |
| MX2024004438A (es) | Inhibidores de integrinas y usos de los mismos en combinacion con otros agentes. | |
| CR20230553A (es) | Regímenes de dosificación expandidos para inhibidores de integrina | |
| GEAP202415866A (en) | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| PH12021552533A1 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| WO2024155965A3 (en) | Biomarkers for use in integrin inhibitor therapy | |
| TW200639159A (en) | Treatment of pain | |
| MX2020004588A (es) | Inhibidor de proteasa de doble cabeza. | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. |